Medical/Pharmaceuticals
Ascletis Selects Its First Oral GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development
- Utilizing Ascletis' Peptide Oral Transport ENhancement Technology (POTENT), ASC37 oral tablets achieved average absolute oral bioavailability of 4.2%, approximately 9-, 30-, and 60-fold higher than semaglutide, tirzepatide, and retatrutide in the oral SNAC formulation, respectively, in head-to...
2025-11-30 18:15
2066
HZICC：Innovation hub: Hangzhou witness new voices and new ambitions
HANGZHOU, China, Nov. 28, 2025 /PRNewswire/ -- The remarkable achievements of past winners of Hangzhou's Innovation & Entrepreneurship Competition for Overseas Talents have set a powerful example, inspiring a new wave of international innovators to bring their projects toHangzhou. Among this yea...
2025-11-28 21:25
1306
HZICC：Unlocked potential: why global innovators choose Hangzhou
HANGZHOU, China, Nov. 28, 2025 /PRNewswire/ -- Meng Jintao, winner of the 2024 Hangzhou's Innovation & Entrepreneurship Competition for Overseas Talents, exemplifies this journey. His project on "All-Iron Redox Flow Battery Technology"--dubbed a "giant movable power bank"--has already secured let...
2025-11-28 21:19
1451
BioDlink Showcases Europe-China CMC Collaboration Amid Developmental Breakthrough
* Recognized as Biologics CDMO of the Year, BioDlink shares insights into the world's first approved EGFR-targeted ADC for recurrent/metastatic nasopharyngeal carcinoma * The company enables seamless Europe–China tech transfer and faster biologics development through an integrated, end-to-end...
2025-11-28 21:00
1577
Inaticabtagene Autoleucel (YORWIDATM) New Drug Application for Lymphoma Approved, China's innovative CAR-T Enters a New Era of Dual Indications
BEIJING, Nov. 28, 2025 /PRNewswire/ -- On November 28, 2025, Juventas Cell Therapy Co., Ltd. (hereinafter referred to as "Juventas") announced that its independently developed CAR-T cell therapy product, Inaticabtagene Autoleucel ( Ina-cel) (tradename: YORWIDATM), has received new drug marketing a...
2025-11-28 20:52
1516
K-Beauty & K-MediTech Expo Malaysia 2025 Concludes Successfully, Strengthening Korea-Malaysia Collaboration Across Beauty and Healthcare Sectors
PENANG, Malaysia, Nov. 28, 2025 /PRNewswire/ -- K-Beauty Expo Malaysia 2025 and K-MediTech Expo Malaysia 2025, hosted by Gyeonggi Province and organised by KINTEX, have successfully concluded at the Penang Waterfront Convention Centre (PWCC) after a dynamic three-day showcase of Korea's leading b...
2025-11-28 20:11
1615
Tianlong Strengthens Transfusion Safety with Innovative Blood Screening Solutions on World AIDS Day 2025
XI'AN, China, Nov. 28, 2025 /PRNewswire/ -- On World AIDS Day 2025, Tianlong reiterates its commitment to advancing global transfusion safety by presenting its fully integrated nucleic acid blood screening solution. Combining high automation with high-sensitivity NAT reagents, the solution enable...
2025-11-28 18:33
1460
OMRON Healthcare Surpasses 50 Million Nebulizers Sold
- Easing Burden of Respiratory Diseases Worldwide since 1978 - KYOTO, Japan, Nov. 28, 2025 /PRNewswire/ -- OMRON HEALTHCARE Co., Ltd., a global leader in the field of clinically proven, innovative medical equipment for home health monitoring and treatment, announced that cumulative sales of its ...
2025-11-28 16:00
1206
Imugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva® Combination in Solid Tumours
* Imugene and JW Therapeutics (Shanghai) Co., LTD have entered a strategic collaboration to evaluate a novel combination therapy using Imugene's onCARlytics (CF33-CD19) oncolytic virus and JW's CD19 CAR-T cell therapy, Carteyva®, in refractory solid tumors. * The collaboration includes precli...
2025-11-28 13:00
1400
The Annals of Oncology Publishes Results of Phase II Study of Sacituzumab Tirumotecan Monotherapy for Urothelial Carcinoma
CHENGDU, China, Nov. 28, 2025 /PRNewswire/ -- Recently, Clinical study results from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", HKEX: 6990)'s TROP2 ADC sacituzumab tirumotecan (sac-TMT) monotherapy for advanced or metastatic urothelial carcinoma (UC) patients has been publ...
2025-11-28 12:32
2466
Keep Your Respiratory Health Strong This Season With VARON Black Friday Offers
NEW YORK, Nov. 27, 2025 /PRNewswire/ -- As the holiday season approaches,
respiratory health becomes a top priority for individuals living with chronic
conditions such as COPD, sleep apnea, or other lung diseases. VARON,
2025-11-28 06:09
1421
Strategic Partnership | Sanyou Bio and Korea's FatiAbGen Join Forces to Expand the Global Biopharma Market
SHANGHAI, Nov. 27, 2025 /PRNewswire/ -- Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. ("Sanyou Bio") andSouth Korea's FatiAbGen Co., Ltd. today jointly announced the signing of a comprehensive strategic collaboration agreement covering joint project development, exclusive representation in the K...
2025-11-27 22:00
2106
Once-Monthly GLP-1 RA | Gan & Lee Pharmaceuticals Initiates Phase 3 Clinical Study (GRADUAL-3) of the First Chinese Once-Monthly GLP-1 RA for Weight Management
BEIJING, Nov. 27, 2025 /PRNewswire/ -- Gan & Lee Pharmaceuticals (Gan & Lee, stock code: 603087.SH) announced the initiation of GRADUAL-3, its third large-scale phase 3 clinical study of the glucagon-like peptide-1 receptor agonist (GLP-1 RA) bofanglutide (research code: GZR18) injection in adult...
2025-11-27 16:57
1169
IASO Bio Announces BLA Approval of Fucaso (Equecabtagene Autoleucel) by the Hong Kong Department of Health for the Treatment of Relapsed or Refractory Multiple Myeloma
SHANGHAI and NANJING, China and PLEASANTON, Calif., Nov. 27, 2025 /PRNewswire/ -- IASO Biotechnology ("IASO Bio"), a commercial-stage biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of novel cell therapies and biologics for hematologic mali...
2025-11-27 13:44
1305
SK Biopharmaceuticals Expands Radiopharmaceutical Therapy Portfolio with Second In-licensed Candidate from Wisconsin Alumni Research Foundation
New addition strengthens SK Biopharmaceuticals' radiopharmaceutical therapy portfolio and reinforces its R&D capabilities through global partnerships and value chain integration SEOUL, South Korea, Nov. 26, 2025 /PRNewswire/ -- SK Biopharmaceuticals, CO., Ltd., a biotech company specializing in ...
2025-11-27 10:39
1298
Patronus Biotech receives grant to evaluate a novel malaria vaccine and adjuvant to support affordable access and use in global health
SINGAPORE, Nov. 27, 2025 /PRNewswire/ -- Patronus Biotech today announced a grant from the Gates Foundation to accelerate the development of its novel malaria vaccine and adjuvant program to support affordable access and use in global health. The funding will enable the evaluation of an innovativ...
2025-11-27 09:00
1073
TCI Biotech Inaugurates Advanced Performance Nutrition Research Center, Expands Into Brain Science to Accelerate Next-Generation Health Innovation
SALT LAKE CITY, Nov. 26, 2025 /PRNewswire/ -- TCI Biotech (TCI Co., Ltd.), a global CDMO+ specializing in functional foods, nutraceuticals, and beauty supplementation, today announced the launch of the TCI Advanced Performance Nutrition Research Center, a new innovation hub focused on high-perfor...
2025-11-27 00:00
1544
Healgen Scientific Spotlights the Rapid Check® COVID-19/Flu A&B Antigen Test to Help Families Stay Prepared for the Respiratory Virus Season
HOUSTON, Nov. 26, 2025 /PRNewswire/ -- As the holiday season approaches, gatherings among family and friends are expected to increase the risk of respiratory virus transmission, including COVID-19 and influenza. In response, Healgen® Scientific highlights the Rapid Check® COVID-19/Flu A&B Antigen ...
2025-11-27 00:00
1039
Celltrion announces publication of post-hoc analysis of LIBERTY-CD study of ZYMFENTRA® (infliximab-dyyb), indicating consistent efficacy across disease location, including the terminal ileum in Clinical Gastroenterology and Hepatology journal
* Findings from the post-hoc analysis of LIBERTY-CD study indicates efficacy of ZYMFENTRA® (subcutaneous infliximab) regardless of disease location, consistent across ileum-dominant and colon-dominant Crohn's disease (CD) * Findings support the therapeutic potential of ZYMFENTRA in addressing ...
2025-11-26 14:48
2570
Vital Signs highlights how researchers are "cracking the code on the genome" to harness the biomedical superpowers of hibernating animals
HONG KONG, Nov. 26, 2025 /PRNewswire/ -- In a groundbreaking new episode, CNN's long-running seriesVital Signs delves into the cutting-edge science of hibernation, revealing how the secrets of the animal kingdom could unlock revolutionary advancements in human health, from fighting cancer and hea...
2025-11-26 14:44
1654
Week's Top Stories
Most Reposted
Marina Bay precinct partners UOB, Marina Bay Sands and Singapore Tourism Board, together with Disney Cruise Line, to illuminate Singapore's skyline with a fireworks sky show
[Picked up by 328 media titles]
2026-02-19 14:30
Never Miss a Message: Agoda's Customer Support Now Travels With You
[Picked up by 326 media titles]
2026-02-24 12:00
NextFin Asia: A New Dedicated Fund for the Catapult: Inclusion SE Asia Program to Further Scale Inclusive Finance Fintechs in ASEAN
[Picked up by 311 media titles]
2026-02-23 08:00
Klook and Osaka Convention & Tourism Bureau sign MoU to advance inbound tourism and foster socio-economic development throughout Osaka Prefecture
[Picked up by 301 media titles]
2026-02-24 16:13
Vitafoods Asia 2026 Expands by 30%: A Bigger, More Dynamic Trade Event with Exciting New Features & Increased International Participation
[Picked up by 288 media titles]
2026-02-23 10:09